Demographic and clinical features of study cohort
| dcSSc | ||||
|---|---|---|---|---|
| Normal platelets (n=19) | High platelets (n=20) | lcSSc (n=29) | Controls (n=15) | |
| Gender (M/F) | 5 / 14 | 4 / 16 | 1 / 28 | 7 / 8 |
| Age (years,mean±sd) | 53.8 ± 9.6 | 56.3 ± 10.9 | 59.1 ± 11.4 | 53.7 ± 11.4 |
| Duration of Disease (months,mean±SEM) | 47.3 ± 6.9 | 57.0 ± 11.9 | 152.6 ± 23.9 | |
| Duration of Raynaud's (months,mean±SEM) | 57.6 ± 8.8 | 64.5 ± 13.2 | 147.5 ± 29.5 | |
| Organ Involvement, % | ||||
| Oesophageal | 84 | 60 | 62 | |
| Other gastrointestinal | 26 | 25 | 38 | |
| Lung | 42 | 55 | 17 | |
| Muscle | 5 | 15 | 0 | |
| Joint | 5 | 10 | 0 | |
| Renal | 5 | 8 | 7 | |
| Cardiac | 0 | 25 | 0 | |
| Serology, % | ||||
| Antinuclear | 100 | 100 | 97 | |
| Anticentromere | 0 | 0 | 66 | |
| Antitopoisomerase 1 | 32 | 55 | 7 | |
| AntiRNA polymerase | 32 | 30 | 7 | |
| Other | 26 | 10 | 10 | |
Thrombocytosis defined by platelet count above mean of 450 × 109/L.